Human epidermal growth factor receptor Her-2 and the rodent counterpart neu (Her-2/neu) amplification/overexpression drives the malignant transformation and cell survival of several cancers, including breast, gastric pancreatic and salivary duct cancers, therefore, it represents an important target in anti-cancer therapy [1]. Here, ERBB2 is linked to cancer.